All News
What's New in Spondyloarthritis
Dr. Arthur Kavanaugh and Dr. Eric Ruderman gave an update on what's new in spondyloarthritis at the 2026 Rheumatology Winter Clinical Symposium (RWCS) in Maui, Hawaii. Here's a summary.
Read Article
Disease Modification, Disparities and the Next Therapeutic Frontier in Gout
Gout management has entered what Dr. Robert Terkeltaub MD from UC San Diego described as its “disease-modifying era,” during his talk at RheumNow Live 2026. In a recent comprehensive review of the past, present, and future of gout therapy, the central message was clear: “We can really apply disease modification to gout based on prospective, randomized controlled trials.”
Read Article
RT @gibson_rheumPAC
Who should be tested?
Test only if you plan to treat.
Indications include:
• Active or prior ulcers
• MALT lymphoma
• Gastric cancer
• Chronic atrophic gastritis
Avoid indiscriminate testing.
#RNL26 atoid arthritis https://t.co/2KJluSAPNx
Dr. John Cush RheumNow ( View Tweet)
Genentech announced results of Phase III, MAJESTY OL study of obinutuzumab vs tacrolimus in 142 pts w/ primary membranous nephropathy & found signif more complete remissions at 2 yrs in obintuzumab Rx pts. Obintuzumab (Gazyva) if FDA approved for lupus nephritis. https://t.co/maJbvUCkBe
Dr. John Cush RheumNow ( View Tweet)
Screening study of lung US (LUS) vs HRCT in 73 RA pts (DAS28 3.47) Chest HRCT identified ILD in 29%. LUS identified ILD in 22% of patients. LUS sensitivity was 59%; specificity 94%. ROC. This study demonstrates the good diagnostic performance of LUS in RA- ILD detection https://t.co/E8avnbvUiw
Dr. John Cush RheumNow ( View Tweet)
Rotator cuff abnormalities are nearly universal after age 40, & incr w/ age; routine imaging should not guide Dz or Tx of atraumatic shoulder pain. Study of 602 having MRI (58yrs) RC abnormalities in 98.7%;; 25% tendinopathy, 62% Partial & 11% Full thickness tears https://t.co/Jw9rMUQBLs
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Arthroplasty risks in RMD
AxSpA - Respiratory complications (OR 1.7), PNA (2.2)
SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity
PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Inflammatory arthritis pts getting TKA:
- increased risk of RBC transfusion (OR 1.39), infection (1.64) and readmission (1.46)
- THA: also risk of mechanical complications (like dislocation) OR 1.3 https://t.co/ovW2C2EuXF
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
UIP pattern RA-ILD is where the big problem is. We are less good at treating this. Perhaps the newer agents such as nerandomilast will change this? #RNL26 https://t.co/Z0BXxyNrCI
Dr. John Cush RheumNow ( View Tweet)
RNL 26 Report: Spondyloarthritis
Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, about lectures presented during the "Staying Ahead of Spondyloarthritis" session.
https://t.co/UjvauWoga5 https://t.co/Zv8dmUuVyD
Dr. John Cush RheumNow ( View Tweet)
Obesity, Surgery, and Optimizing Patient Care
Rheumatologic care requires a multidisciplinary approach and collaboration with other specialties to treat complex systemic diseases. While many Pods at RheumNow Live are disease-specific, the Pod II focused on Advancing Practice on https://t.co/hvSY5yHZmd
Dr. John Cush RheumNow ( View Tweet)
The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field.
https://t.co/KuVei8jiFu https://t.co/PR4h2qniEL
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
Comparative survival in incident RA-ILD 1955-1995 vs 1999-2014. We are getting better, althoug need to take into account the general survival improvement also. More work to do! #RNL26 https://t.co/VwV33tHgR8
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26 @RheumNow
Uzma Haque
GLP1 on pts with SLE and diabetes
Retrospective study - major improvements in
MACE HR 0.66
VTE HR 0.49
Renal progession HR 0.77
Mortality HR 0.26
A major tool for rheumatic care! https://t.co/qR3HKfsugZ
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC
Helicobacter pylori Update: H. Pylori remains the most common chronic bacterial infection worldwide, acquired in childhood and lifelong if untreated. Its clinical impact spans far beyond dyspepsia—from ulcers to malignancy. #RNL26 tis
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC Gout flares are not benign. Recent flares double MI/stroke risk and markedly increase CV mortality—making flare prevention vital.#RNL26 https://t.co/gKvqo3vFYb
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC
Baseline serum urate >8–9 mg/dL strongly predicts worse flares, hospitalizations, and joint damage over years. Urate level should inform urgency and intensity of therapy. #RNL26 https://t.co/4RBVXZxCCX
Dr. John Cush RheumNow ( View Tweet)
“The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.”
- Martin Luther King, Jr.
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC
Arthur Kavanaugh’s RheumNow 2026: Why Do Plain X-Rays in Psoriatic Arthritis? Thought-provoking session on the role of plain radiographs in psoriatic arthritis—not as relics of the past, but as tools that still inform prognosis, function, and long-term
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_RheumPAC
Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush RheumNow ( View Tweet)
